Current Report Filing (8-k)
May 19 2016 - 4:12PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report: (Date of earliest event reported)
May
18, 2016
ARIAD
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-36172
|
22-3106987
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
26 Landsdowne Street, Cambridge, Massachusetts
|
02139
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(617) 494-0400
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (
see
General Instruction A.2. below):
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
In a press release dated May 18, 2016, ARIAD Pharmaceuticals, Inc.
announced its schedule of events at the Annual Meeting of the American
Society of Clinical Oncology (ASCO) conference being held in Chicago
from June 3 to 7, 2016, and disclosed highlights from the abstract on
its ALTA trial of brigatinib to be presented in an oral session on June
6, 2016. The data in the abstract is as of December 7, 2015, and the
data in the oral session will be updated as of February 29, 2016. A copy
of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
|
ITEM 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press release dated May 18, 2016
|
The press release may contain hypertext links to information on our
websites. The information on our websites is not incorporated by
reference into this Current Report on Form 8-K and does not constitute a
part of this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
ARIAD Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
Date:
|
May 18, 2016
|
|
By:
|
/s/ Manmeet S. Soni
|
|
|
|
|
Manmeet S. Soni
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
Exhibit List.
|
|
Exhibit
|
|
Description
|
|
|
|
|
|
|
|
99.1
|
|
Press release dated May 18, 2016
|
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Apr 2023 to Apr 2024
